243 related articles for article (PubMed ID: 11996903)
1. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo.
Guise TA; Yin JJ; Thomas RJ; Dallas M; Cui Y; Gillespie MT
Bone; 2002 May; 30(5):670-6. PubMed ID: 11996903
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
3. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells.
Sterling JA; Oyajobi BO; Grubbs B; Padalecki SS; Munoz SA; Gupta A; Story B; Zhao M; Mundy GR
Cancer Res; 2006 Aug; 66(15):7548-53. PubMed ID: 16885353
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of osteolytic bone metastases.
Guise TA
Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
[TBL] [Abstract][Full Text] [Related]
7. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
Saito H; Tsunenari T; Onuma E; Sato K; Ogata E; Yamada-Okabe H
Anticancer Res; 2005; 25(6B):3817-23. PubMed ID: 16309168
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
Yin JJ; Selander K; Chirgwin JM; Dallas M; Grubbs BG; Wieser R; Massagué J; Mundy GR; Guise TA
J Clin Invest; 1999 Jan; 103(2):197-206. PubMed ID: 9916131
[TBL] [Abstract][Full Text] [Related]
9. Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases.
Ponnapakkam T; Anbalagan M; Stratford RE; Rowan BG; Gensure RC
Anticancer Drugs; 2021 Apr; 32(4):365-375. PubMed ID: 33595947
[TBL] [Abstract][Full Text] [Related]
10. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.
Bendre MS; Gaddy-Kurten D; Mon-Foote T; Akel NS; Skinner RA; Nicholas RW; Suva LJ
Cancer Res; 2002 Oct; 62(19):5571-9. PubMed ID: 12359770
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
12. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
13. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
14. Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo.
Rabbani SA; Khalili P; Arakelian A; Pizzi H; Chen G; Goltzman D
Endocrinology; 2005 Jul; 146(7):2885-94. PubMed ID: 15831570
[TBL] [Abstract][Full Text] [Related]
15. The parathyroid hormone-related protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis.
Bouizar Z; Spyratos F; De vernejoul MC
J Bone Miner Res; 1999 Mar; 14(3):406-14. PubMed ID: 10027905
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
19. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
[TBL] [Abstract][Full Text] [Related]
20. [Bone metastases: pathogenesis and treatment with diphosphonates].
Body JJ
Bull Mem Acad R Med Belg; 1997; 152(3):169-74; discussion 174-6. PubMed ID: 9491638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
